quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:35:00·9d
PRRelease
Cellectar Biosciences Inc. logo

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

CLRB· Cellectar Biosciences Inc.
Health Care
Original source

Companies

  • CLRB
    Cellectar Biosciences Inc.
    Health Care

Recent analyst ratings

  • Mar 10UpdateMaxim Group$10.00
  • Dec 5UpdateLadenburg Thalmann$13.00

Related

  • PR2d
    Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
  • ANALYST44d
    Cellectar Biosciences upgraded by Maxim Group with a new price target
  • SEC50d
    Cellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • SEC50d
    SEC Form 10-K filed by Cellectar Biosciences Inc.
  • PR50d
    Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
  • PR57d
    Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
  • PR65d
    Cellectar Biosciences Expands Global Intellectual Property Estate
  • PR104d
    Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022